Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease

clinical trial

Details

Instance of: clinical trial
Start time: May 2020
End time: October 2023
Main subject: coronary artery disease, peripheral artery disease, atherosclerosis, ischemia
clinical trial phase: phase III clinical trial
maximum age: 75
minimum age: 45
number of participants: 200
research intervention: montelukast
short name: CADET-PAD
study type: interventional study
title: The Assessment of Cysteinyl Leukotriene Receptor Antagonist Role in Inhibition of Atherosclerosis, Proliferation and Its Influence on Endothelial Function in Patients Undergoing Endovascular Treatment Due to Peripheral Arterial Disease.

Nothing in the MetaHistoryBook collection references this item yet.